David Patience Sells 13,296 Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CFO David Patience sold 13,296 shares of the firm’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $0.87, for a total transaction of $11,567.52. Following the completion of the transaction, the chief financial officer now directly owns 50,419 shares of the company’s stock, valued at approximately $43,864.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

David Patience also recently made the following trade(s):

• On Monday, February 26th, David Patience sold 350 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.96, for a total transaction of $336.00.

Accelerate Diagnostics Price Performance

NASDAQ:AXDX opened at $0.90 on Friday. The firm has a market capitalization of $19.49 million, a P/E ratio of -0.18 and a beta of 0.52. Accelerate Diagnostics, Inc. has a 1-year low of $0.83 and a 1-year high of $11.90. The company’s fifty day moving average price is $1.03 and its 200-day moving average price is $3.36.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Craig Hallum decreased their price target on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating for the company in a report on Monday, April 1st. William Blair reaffirmed an “outperform” rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd. Finally, StockNews.com started coverage on shares of Accelerate Diagnostics in a report on Friday. They issued a “hold” rating for the company.

Institutional Trading of Accelerate Diagnostics

A number of hedge funds and other institutional investors have recently made changes to their positions in AXDX. Vanguard Group Inc. increased its stake in shares of Accelerate Diagnostics by 22.6% in the third quarter. Vanguard Group Inc. now owns 2,825,643 shares of the medical research company’s stock worth $4,295,000 after acquiring an additional 520,656 shares during the period. Tejara Capital Ltd acquired a new stake in Accelerate Diagnostics during the fourth quarter valued at $185,000. Baird Financial Group Inc. grew its position in Accelerate Diagnostics by 15.5% during the first quarter. Baird Financial Group Inc. now owns 1,741,547 shares of the medical research company’s stock valued at $2,508,000 after buying an additional 233,478 shares during the period. Morgan Stanley grew its position in Accelerate Diagnostics by 598.9% during the fourth quarter. Morgan Stanley now owns 257,489 shares of the medical research company’s stock valued at $182,000 after buying an additional 220,646 shares during the period. Finally, Two Sigma Investments LP acquired a new stake in Accelerate Diagnostics during the third quarter valued at $329,000. Institutional investors and hedge funds own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.